Why is BillionToOne (BLLN) stock down today?

BillionToOne (BLLN) fell roughly 39% on August 6, 2026, dropping from a previous close of $149.97 to trade as low as $90.12 before settling around $91.65. The collapse came shortly after the company reported Q2 2026 earnings — swinging to profitability — and reaffirmed its full-year 2026 revenue outlook, but the market's reaction suggests investors questioned whether the pre-drop share price was justified by those results.

Investor's Business Daily described the session as BillionToOne 'plummeting 38%, leading a medtech sell-off,' with related medtech names such as GRAL and CAI also trading lower. The stock was simultaneously flagged as one of the day's top midday decliners and was described in a Biotech IPO context in live market coverage, indicating that scrutiny of its post-IPO valuation was a central theme driving the sell-off.

A Simply Wall St. analysis published the same day directly asked whether BillionToOne can 'justify its price on earnings and reaffirmed 2026 guidance,' reflecting the core investor concern: that the stock's elevated valuation — with a market cap of approximately $4.22 billion — requires growth well beyond what the reaffirmed guidance signals. Q1 2026 revenue was $108.4 million, representing flat year-over-year growth, which may have further pressured sentiment heading into the Q2 report.

The broader market was not a significant factor in the sell-off. The S&P 500 (^GSPC) fell just 0.18% and the Nasdaq-100 (QQQ) declined 0.37% on the day — meaning the roughly 39-point drop in BLLN was overwhelmingly company-specific rather than a reflection of broad market weakness.

As of the close of trading on August 6, BLLN was down approximately 39% on the day, with the trading range spanning $90.12 to $105.35. The company's 2026 revenue guidance remains reaffirmed per management's statements, but the market's reaction indicates investors are reassessing how much growth premium the stock can command at current levels.